Xenon files epilepsy NDA as depression study setback weighs

Xenon files epilepsy NDA as depression study setback weighs: the analysis positions AXSM, RLMD and CMPS to benefit and XENE, JAZZ and PRAX under pressure; confidence high.

Analyzed 2026-09-18 — point-in-time, never revised. Outcomes are scored against SPY and published either way.

Ranked exposures

▼ XENE Xenon Pharmaceuticals — impact -85 · confidence high · horizon immediate · 1st order
Xenon loses azetukalner’s depression revenue opportunity as paused enrollment delays development and narrows peak sales expectations.
Chain: depression study enrollment paused on safety signal → psychiatry indication timeline extends by years → peak sales model loses depression revenue → epilepsy NDA becomes the sole near-term driver
What would break the call: Xenon resumes depression enrollment after a clean safety review, restoring the psychiatry revenue line.
▲ AXSM Axsome Therapeutics — impact +45 · confidence high · horizon quarters · 2nd order
Axsome preserves Auvelity’s depression prescription growth and pricing power as Xenon’s stalled rival reduces future branded competition.
Chain: Xenon depression program stalls in development → one future branded oral competitor removed → Auvelity faces a thinner rival set → prescription growth and net price hold longer
What would break the call: A payer moves Auvelity to non-preferred status, cutting net price regardless of pipeline competition.
▲ RLMD Relmada — impact +40 · confidence low · horizon quarters · 2nd order
Relmada depression drug volume rises after the Xenon study setback reduces market competition.
Chain: rival novel antidepressant mechanism delayed → late-stage depression field narrows → Relmada pipeline scarcity value rises
What would break the call: Relmada reports its own trial failure or funding shortfall, erasing any competitive benefit.
▼ JAZZ Jazz Pharmaceuticals — impact -36 · confidence medium · horizon quarters · 2nd order
Jazz faces slower Epidiolex add-on prescription growth as Xenon’s focal seizure therapy creates an additional oral competitor.
Chain: azetukalner NDA filed for focal seizures → approval adds a novel oral adjunctive option → neurologists shift add-on therapy choices → Epidiolex refractory add-on growth slows
What would break the call: FDA issues a complete response letter on the azetukalner NDA, delaying any launch.
▼ PRAX Praxis Precision Medicines — impact -30 · confidence low · horizon quarters · 2nd order
Praxis competes for the same refractory focal seizure patients, and an approved potassium channel opener compresses pricing for later entrants.
Chain: approved potassium channel opener reaches focal seizure market → refractory patients enrolled by an approved therapy → Praxis trials face tougher recruitment and efficacy bar → later entrant pricing power compresses
What would break the call: Praxis reports a strong pivotal seizure readout that clearly beats the new standard.
▲ CMPS Compass Pathways — impact +28 · confidence low · horizon quarters · 3rd order
Compass faces a thinner late-stage depression field, improving the commercial opening for psilocybin therapy if pivotal trials read out positively.
Chain: Xenon depression program paused on safety → late-stage depression pipeline thins → psilocybin therapy gains relative commercial opening → investor value of scarcity rises
What would break the call: Compass pivotal data misses on durability, making competitive positioning irrelevant.
▼ DRUG Bright Minds Biosciences — impact -20 · confidence low · horizon quarters · 2nd order
Bright Minds must recruit refractory epilepsy patients against a therapy nearing approval, raising trial costs and slowing enrollment.
Chain: azetukalner nears approval in focal seizures → refractory epilepsy patients absorbed by approved option → Bright Minds recruitment slows at shared sites → per-patient trial costs rise
What would break the call: Bright Minds reports strong seizure reduction data, making site access a non-issue.
▲ ANRO Alto Neuroscience — impact +20 · confidence low · horizon weeks · 3rd order
Alto's biomarker-guided depression programs meet less competition for trial sites and patients while psychiatry enrollment elsewhere stays paused.
Chain: Xenon pauses psychiatry enrollment → trial sites free capacity for depression studies → Alto recruits patients faster and cheaper → development timelines compress modestly
What would break the call: Alto posts a failed biomarker-guided readout, ending the relevance of enrollment speed.
▼ SUPN Supernus Pharmaceuticals — impact -18 · confidence high · horizon quarters · 2nd order
Supernus loses epilepsy pricing power when Xenon’s differentiated azetukalner enters the focal seizure market.
Chain: novel oral adjunctive antiseizure drug filed → launch adds branded competition in focal seizures → Supernus epilepsy franchise loses share of new starts → discounting pressure grows on branded scripts
What would break the call: Azetukalner approval is delayed or its label restricts use to narrow refractory patients.
▲ ATAI atai Life Sciences — impact +18 · confidence low · horizon weeks · 3rd order
atai gains relative pipeline scarcity in treatment-resistant depression as another novel oral mechanism runs into safety trouble.
Chain: novel antidepressant mechanism stalls on safety → late-stage depression competitive field thins → atai psychedelic programs gain relative scarcity value
What would break the call: atai reports weak durability data, which removes any competitive positioning benefit.
▲ NMRA Neumora Therapeutics — impact +18 · confidence low · horizon weeks · 3rd order
Neumora's kappa opioid depression program gains scarcity value as another novel antidepressant mechanism runs into neuropsychiatric safety trouble.
Chain: neuropsychiatric safety issue stalls a rival mechanism → novel antidepressant field thins further → Neumora kappa program gains scarcity value
What would break the call: Neumora reports another phase three miss in depression, removing pipeline value.
▼ NPCE NeuroPace — impact -15 · confidence low · horizon quarters · 3rd order
NeuroPace implant volumes slow as neurologists exhaust a new drug class before recommending responsive neurostimulation surgery.
Chain: new oral antiseizure drug reaches market → neurologists try an added drug line first → surgical referral for neurostimulation is deferred → NeuroPace implant volumes grow slower
What would break the call: NeuroPace wins broader indication coverage that pulls patients to devices earlier.
▼ OVID Ovid Therapeutics — impact -15 · confidence low · horizon quarters · 2nd order
Ovid's epilepsy candidates confront a higher efficacy bar and tougher site competition from a drug now under review.
Chain: approved competitor raises the seizure efficacy bar → Ovid trials need larger effect sizes → site and patient competition intensifies → development risk and cost rise
What would break the call: Ovid reports differentiated data in a genetic epilepsy niche that avoids direct overlap.
▲ JNJ Johnson & Johnson — impact +15 · confidence medium · horizon weeks · 3rd order
Johnson & Johnson sustains Spravato volume growth and existing net prices as Xenon’s halted depression program removes a future oral competitor.
Chain: Xenon oral depression candidate delayed → future oral competition to Spravato recedes → Spravato volume and net price hold → psychiatry franchise growth persists
What would break the call: Generic or competing esketamine entry pressures Spravato pricing independently of pipeline news.
▲ ABBV AbbVie — impact +15 · confidence low · horizon weeks · 3rd order
Cariprazine preserves its position in adjunctive depression treatment as azetukalner's psychiatric development timeline extends.
Chain: azetukalner psychiatry timeline extends → adjunctive depression competition arrives later → cariprazine keeps adjunctive share longer
What would break the call: Vraylar loses exclusivity or payer preference, which dominates any pipeline competition effect.
▼ LIVN LivaNova — impact -14 · confidence low · horizon quarters · 3rd order
LivaNova's vagus nerve stimulation referrals shrink when drug-resistant patients gain another effective oral option before device implantation.
Chain: new oral antiseizure option enters practice → drug-resistant patients try another medication first → vagus nerve stimulation referrals are delayed → LivaNova epilepsy device revenue growth slows
What would break the call: LivaNova reports accelerating implant volumes after approval, disproving the referral delay.
▼ HRMY Harmony Biosciences — impact -12 · confidence low · horizon quarters · 2nd order
Harmony is advancing an epilepsy candidate and now competes for the same neurologist attention and refractory trial patients.
Chain: azetukalner filed for focal seizures → refractory epilepsy patients absorbed into approved therapy → Harmony epilepsy trials recruit more slowly → pipeline launch economics weaken
What would break the call: Harmony epilepsy assets target narrow genetic syndromes with no patient overlap.
▲ BIIB Biogen — impact +12 · confidence low · horizon quarters · 3rd order
Biogen's Zurzuvae franchise encounters a thinner pipeline of novel oral antidepressants, supporting durable pricing and prescriber attention.
Chain: novel oral antidepressant program stalls → competitive pipeline in mood disorders thins → Zurzuvae keeps prescriber attention and price
What would break the call: Zurzuvae uptake disappoints on access and reimbursement, which drives the franchise more than rivals.
▲ NBIX Neurocrine Biosciences — impact +12 · confidence low · horizon quarters · 3rd order
Neurocrine's early depression assets face one fewer differentiated rival, improving the long-term revenue case for its psychiatry pipeline.
Chain: Xenon psychiatry asset delayed indefinitely → fewer differentiated rivals in depression → Neurocrine early psychiatry assets gain value
What would break the call: Neurocrine discontinues its depression assets, removing the pipeline benefit entirely.
▼ VTRS Viatris — impact -10 · confidence low · horizon quarters · 3rd order
Viatris sells generic antiseizure products that lose refractory patient volume when a branded differentiated oral therapy launches.
Chain: branded novel antiseizure drug approved → refractory patients shift off generic regimens → Viatris generic epilepsy volumes drift lower
What would break the call: Step therapy rules keep generics first line, preserving Viatris prescription volumes.
▼ MEDP Medpace — impact -8 · confidence low · horizon weeks · 2nd order
Medpace runs mid-cap biotech trials and loses billable work when a large psychiatry study pauses enrollment.
Chain: sponsor pauses depression study enrollment → site activation and monitoring work slows → contract research backlog conversion softens
What would break the call: Enrollment resumes quickly or the contract is not material to Medpace backlog.
▼ STOK Stoke Therapeutics — impact -8 · confidence low · horizon quarters · 3rd order
Stoke's genetic epilepsy programs compete for the same specialist prescribing budgets once a broad adjunctive therapy launches.
Chain: broad adjunctive antiseizure therapy launches → specialist prescribing attention shifts to new drug → Stoke genetic epilepsy launch faces crowded channel
What would break the call: Stoke zorevunersen data show large seizure reduction in Dravet, isolating it from oral competition.
▼ TEVA Teva — impact -8 · confidence low · horizon quarters · 3rd order
Generic antiseizure volumes erode gradually as prescribers shift refractory patients toward a branded potassium channel opener.
Chain: branded potassium channel opener approved → refractory patients moved off generic regimens → generic antiseizure prescription volumes erode slowly
What would break the call: Payers require multiple generic failures before branded access, preserving generic volumes.
▲ ACAD Acadia Pharmaceuticals — impact +7 · confidence low · horizon quarters · 3rd order
Acadia neuropsychiatry assets face one fewer novel oral rival for prescriber attention and payer formulary slots.
Chain: rival psychiatry program delayed indefinitely → fewer novel entrants compete for formulary slots → Acadia neuropsychiatry pipeline value improves
What would break the call: Acadia pipeline setbacks or Nuplazid generic entry dominate the competitive effect.

Sources

What happened

Horizon	Verdict	Top pick	Excess vs SPY
1 trading days	Mixed	AXSM	-2.9% vs SPY
5 trading days	Wrong	AXSM	-9.1% vs SPY

Related scenarios

Stocks in this scenario

XENE · AXSM · RLMD · JAZZ · PRAX · CMPS · DRUG · ANRO · SUPN · ATAI · NMRA · NPCE · OVID · JNJ · ABBV · LIVN · HRMY · BIIB · NBIX · VTRS · MEDP · STOK · TEVA · ACAD

News events · All scenarios · Pricing · Track record · Methodology · Map your own scenario